ORLANDO HEALTH
- Type
- Teaching hospital
- Where
- Orlando, FL
- Medicare CCN
- 100006
- Received
- $1,642,091 in 418 records, 2019 ($297,072 general, $1,345,018 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Orlando Health, Inc. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, LLC Fuzzy (name and state)
- Nonprofit contractor: Orlando Health Inc Fuzzy (name and state)
- Plan sponsor: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Federal award recipient: ORLANDO HEALTH, INC Fuzzy (name and state)
- Federal award recipient: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying registrant: ORLANDO HEALTH Fuzzy (name and state)
- Nonprofit: ORLANDO HEALTH INC Fuzzy (name and state)
- Patent assignee: Orlando Health, Inc. Fuzzy (name and state)
- Trademark owner: Orlando Health, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 62 | $297,072 |
| 2019 | Research payment | 356 | $1,345,018 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 356 | $1,345,018 |
| Grant | 11 | $105,767 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 13 | $77,596 |
| Royalty or License | 1 | $46,941 |
| Gift | 15 | $30,253 |
| Space rental or facility fees (teaching hospital only) | 12 | $21,100 |
| Consulting Fee | 3 | $8,200 |
| Education | 5 | $6,521 |
| Charitable Contribution | 1 | $394 |
| Food and Beverage | 1 | $298 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Medline Industries LP | $16,224 | Research payment | Cash or cash equivalent | Self Care Kits (119 Cases), Assisted Care Kiets (17 cases), Denture Care Kits (11 cases) | 2019 | |
| 2019-12-31 | Stryker Corporation | $9,176 | Gift | In-kind items and services | HIP ARTHROSCOPY ACCESS & INSTRUMENTATION SET Device, ARTHROSCOPY | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $6,501 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as | 2019 |
| 2019-12-31 | Edwards Lifesciences Corporation | $1,511 | Education | In-kind items and services | HemoSphere advanced monitoring platform Device, Noninvasive Hemodynamic Monitoring | 2019 | |
| 2019-12-31 | Stryker Corporation | $782 | Gift | In-kind items and services | BARI 10-A Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | Stryker Corporation | $648 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $648 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $648 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $648 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $528 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $394 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $107 | Research payment | In-kind items and services | MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial | 2019 | |
| 2019-12-31 | Masimo Corporation | $86 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2019 | |
| 2019-12-31 | Stryker Corporation | $5 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $2,025 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-12-26 | Abbott Laboratories | $4,150 | Research payment | Cash or cash equivalent | HeartMate PHP Device, Cardiac Arrhythmias and Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2019 |
| 2019-12-26 | AtriCure, Inc. | $1,500 | Research payment | Cash or cash equivalent | ATRICURE SYNERGY ABLATION SYSTEMS Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE (DEEP) APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT O | 2019 |
| 2019-12-26 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | HeartMate PHP Device, Cardiac Arrhythmias and Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2019 |
| 2019-12-24 | Amgen Inc. | $5,500 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | T-VEC + Pembrolizumab in patients progressing on prior anti-PD-1 therapy | 2019 |
| 2019-12-23 | Janssen Research & Development, LLC | $2,630 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-12-19 | Abbott Laboratories | $5,500 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-19 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | Lupron Depot Drug, Endocrinology | M16-904 | 2019 |
| 2019-12-17 | Medical Device Business Services, Inc. | $5,953 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-17 | CSL Behring | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | Spineology Inc. | $8,075 | Research payment | In-kind items and services | Rampart Duo Interbody Fusion System Device, Orthopedics/Orthopedic Surgery | ACTLIF Clinical Study | 2019 |
| 2019-12-13 | Novocure Inc. | $1,600 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-24 Pivotal, randomized, open -label study of Tumor Treating Fields (TTFields) concurrent with standard of care thera | 2019 |
| 2019-12-13 | AngioDynamics, Inc. | $1,514 | Research payment | Cash or cash equivalent | Device, NanoKnife | DIRECT | 2019 |
| 2019-12-12 | QOL Medical, LLC | $5,735 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUCRAID Drug, CSID | 2019 | |
| 2019-12-11 | EKOS Corporation | $500 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2019 |
| 2019-12-05 | Medical Device Business Services, Inc. | $8,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-05 | AtriCure, Inc. | $1,500 | Research payment | Cash or cash equivalent | ATRICURE SYNERGY ABLATION SYSTEMS Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE (DEEP) APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT O | 2019 |
| 2019-12-05 | PFIZER INC. | $900 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2019 |
| 2019-12-05 | Genentech, Inc. | $749 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-12-03 | Clovis Oncology, Inc. | $7,230 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2019 |
| 2019-12-03 | F. Hoffmann-La Roche AG | $1,400 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2019 |
| 2019-12-02 | Janssen Research & Development, LLC | $2,630 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-12-02 | W. L. Gore & Associates, Inc. | $500 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE Septal Occluder Clinical Study: A Study to evaluate safety and efficacy in the treatment of transcatheter closure o | 2019 |
| 2019-11-27 | ABBVIE INC. | $4,734 | Research payment | Cash or cash equivalent | Lupron Depot Drug, Endocrinology | M16-904 | 2019 |
| 2019-11-26 | BIOTRONIK INC. | $1,000 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2019 | |
| 2019-11-26 | BIOTRONIK INC. | $500 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2019 | |
| 2019-11-25 | Clovis Oncology, Inc. | $648 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Pr | 2019 |
| 2019-11-25 | Genentech, Inc. | $196 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IPATASERTIB IN COMBINATION WITH PACLITAXEL IN TNBC AND HR BREAST CANCER | 2019 |
| 2019-11-18 | B. Braun Medical Inc. | $74 | Gift | Cash or cash equivalent | 2019 | ||
| 2019-11-15 | Novocure Inc. | $2,560 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-24 Pivotal, randomized, open -label study of Tumor Treating Fields (TTFields) concurrent with standard of care thera | 2019 |
| 2019-11-14 | AstraZeneca Pharmaceuticals LP | $12,068 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2019 |
| 2019-11-14 | Shire North American Group Inc | $8,668 | Research payment | Cash or cash equivalent | ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE | 2019 | |
| 2019-11-14 | AtriCure, Inc. | $5,600 | Research payment | Cash or cash equivalent | ATRICURE SYNERGY ABLATION SYSTEMS Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE (DEEP) APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT O | 2019 |
| 2019-11-13 | Abbott Laboratories | $5,456 | Research payment | Cash or cash equivalent | AMPLATZER PFO Occluder Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2019 |
| 2019-11-13 | LivaNova USA, Inc. | $2,750 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-11-12 | Genentech, Inc. | $8,877 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IPATASERTIB IN COMBINATION WITH PACLITAXEL IN TNBC AND HR BREAST CANCER | 2019 |
| 2019-11-12 | Masimo Corporation | $124 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-11-08 | ABBVIE INC. | $282 | Research payment | Cash or cash equivalent | Lupron Depot Drug, Endocrinology | M16-904 | 2019 |
| 2019-11-07 | Merck Sharp & Dohme LLC | $32,400 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A MULTICENTER PHASE 2, OPEN-LABEL TRIAL OF INTRATUMORAL PIL-12 PLUS ELECTROPORATION IN COMBINATION WITH INTRAVENOUS PEMB | 2019 |
| 2019-11-07 | AtriCure, Inc. | $7,540 | Research payment | Cash or cash equivalent | ATRICURE SYNERGY ABLATION SYSTEMS Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE (DEEP) APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT O | 2019 |
| 2019-11-07 | Novocure Inc. | $5,930 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2019 |
| 2019-11-06 | QOL Medical, LLC | $4,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUCRAID Drug, CSID | 2019 | |
| 2019-11-04 | SANOFI US SERVICES INC. | $1,000 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-11-01 | Janssen Research & Development, LLC | $161 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-10-31 | Janssen Research & Development, LLC | $3,434 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-10-31 | Zimmer Biomet Holdings, Inc. | $1,400 | Grant | Cash or cash equivalent | Grants Device, General | 2019 | |
| 2019-10-30 | Bard Peripheral Vascular, Inc. | $330 | Research payment | Cash or cash equivalent | LUTONIX Device, PERIPHERAL VASCULAR | SAFE-DCB REGISTRY BPV14006 | 2019 |
| 2019-10-29 | F. Hoffmann-La Roche AG | $1,249 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2019 |
| 2019-10-25 | Novocure Inc. | $779 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-24 Pivotal, randomized, open -label study of Tumor Treating Fields (TTFields) concurrent with standard of care thera | 2019 |
| 2019-10-23 | Bard Peripheral Vascular, Inc. | $5,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-10-23 | ABBVIE INC. | $2,814 | Research payment | Cash or cash equivalent | Lupron Depot Drug, Endocrinology | M16-904 | 2019 |
| 2019-10-23 | Pulmonx Corporation | $1,950 | Research payment | Cash or cash equivalent | Pulmonx Endobronchial Valve EBV Device, Pulmonology | Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment | 2019 |
| 2019-10-23 | Pulmonx Corporation | $250 | Research payment | Cash or cash equivalent | Pulmonx Endobronchial Valve EBV Device, Pulmonology | Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment | 2019 |
| 2019-10-21 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | CAPTIVATE | 2019 |
| 2019-10-21 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | CAPTIVATE | 2019 |
| 2019-10-18 | ABBVIE INC. | $2,750 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M11-290 | 2019 |
| 2019-10-18 | ABBVIE INC. | $2,000 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M11-290 | 2019 |
| 2019-10-18 | AngioDynamics, Inc. | $266 | Research payment | Cash or cash equivalent | Device, NanoKnife | Examining patterns of use for the NanoKnife Irreversible Electroporation Device in the real world : the NanoKnife Produc | 2019 |
| 2019-10-18 | ABBVIE INC. | $188 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M11-290 | 2019 |
| 2019-10-18 | ABBVIE INC. | $94 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M11-290 | 2019 |
| 2019-10-17 | Shire North American Group Inc | $5,745 | Research payment | Cash or cash equivalent | CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS E | 2019 | |
| 2019-10-15 | SANOFI US SERVICES INC. | $450 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-10-09 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,500 | Grant | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2019 | |
| 2019-10-05 | SANOFI-AVENTIS U.S. LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PRALUENT Drug, CARDIOVASCULAR | 2019 | |
| 2019-10-05 | Amarin Pharma, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Vascepa Drug, Hypertriglyceridemia | 2019 | |
| 2019-10-04 | Bard Peripheral Vascular, Inc. | $20,364 | Research payment | Cash or cash equivalent | BD NEXIVA CLOSED | 2019 | |
| 2019-10-02 | BIOTRONIK INC. | $4,000 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2019 | |
| 2019-10-02 | BIOTRONIK INC. | $3,500 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2019 | |
| 2019-09-30 | Janssen Research & Development, LLC | $3,892 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-09-27 | Amgen Inc. | $13 | Research payment | In-kind items and services | IMLYGIC Biological, Oncology | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-09-26 | Genentech, Inc. | $9,450 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IPATASERTIB IN COMBINATION WITH PACLITAXEL IN TNBC AND HR BREAST CANCER | 2019 |
| 2019-09-26 | Shire North American Group Inc | $7,481 | Research payment | Cash or cash equivalent | CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS E | 2019 | |
| 2019-09-26 | QOL Medical, LLC | $4,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUCRAID Drug, CSID | 2019 | |
| 2019-09-26 | Shire North American Group Inc | $2,000 | Research payment | Cash or cash equivalent | CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS E | 2019 | |
| 2019-09-26 | Shire North American Group Inc | $750 | Research payment | Cash or cash equivalent | CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS E | 2019 | |
| 2019-09-26 | AtriCure, Inc. | $500 | Research payment | Cash or cash equivalent | ATRICURE SYNERGY ABLATION SYSTEMS Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE (DEEP) APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT O | 2019 |
| 2019-09-24 | Zimmer Biomet Holdings, Inc. | $1,450 | Grant | Cash or cash equivalent | Grants Device, General | 2019 | |
| 2019-09-24 | E.R. Squibb & Sons, L.L.C. | $488 | Research payment | Cash or cash equivalent | Ph II III IO Naive Mel lag3 nivo | 2019 | |
| 2019-09-23 | SANOFI US SERVICES INC. | $7,500 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-09-23 | SANOFI US SERVICES INC. | $4,150 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-09-23 | LivaNova USA, Inc. | $650 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-09-18 | PFIZER INC. | $2,217 | Research payment | Cash or cash equivalent | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PART | 2019 |
| 2019-09-18 | E.R. Squibb & Sons, L.L.C. | $1,935 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Monotherapy | 2019 |
| 2019-09-16 | Janssen Research & Development, LLC | $4,500 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-09-11 | PFIZER INC. | $7,358 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY | 2019 |
| 2019-09-11 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $250 | Grant | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2019 | |
| 2019-09-06 | Clovis Oncology, Inc. | $6,074 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-09-06 | Novocure Inc. | $4,430 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2019 |
| 2019-09-06 | Clovis Oncology, Inc. | $500 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-09-06 | Clovis Oncology, Inc. | $284 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-09-06 | Clovis Oncology, Inc. | $179 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-09-06 | Clovis Oncology, Inc. | $55 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-09-04 | Boston Scientific Corporation | $3,000 | Grant | Cash or cash equivalent | GENERAL - STRUCTURAL HEART Device, STRUCTURAL HEART | 2019 | |
| 2019-09-03 | Clovis Oncology, Inc. | $15,473 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2019 |
| 2019-09-03 | Clovis Oncology, Inc. | $6,074 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2019 |
| 2019-09-03 | Clovis Oncology, Inc. | $72 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2019 |
| 2019-09-02 | Janssen Research & Development, LLC | $819 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-08-31 | BIOTRONIK INC. | $16,448 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-08-29 | Janssen Research & Development, LLC | $7,502 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-08-29 | AtriCure, Inc. | $1,895 | Research payment | Cash or cash equivalent | ATRICURE SYNERGY ABLATION SYSTEMS Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE (DEEP) APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT O | 2019 |
| 2019-08-28 | QOL Medical, LLC | $4,572 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUCRAID Drug, CSID | 2019 | |
| 2019-08-27 | Intuitive Surgical, Inc. | $2,400 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-27 | Intuitive Surgical, Inc. | $2,400 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-26 | Clovis Oncology, Inc. | $216 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2019 |
| 2019-08-22 | Janssen Research & Development, LLC | $1,589 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-08-21 | PFIZER INC. | $990 | Research payment | Cash or cash equivalent | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PART | 2019 |
| 2019-08-21 | PFIZER INC. | $125 | Research payment | Cash or cash equivalent | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PART | 2019 |
| 2019-08-19 | Boston Scientific Corporation | $1,900 | Research payment | Cash or cash equivalent | INGENIO Device, BRADY | SAMURAI | 2019 |
| 2019-08-19 | GENZYME CORPORATION | $1,400 | Consulting Fee | Cash or cash equivalent | THYMOGLOBULIN Drug, ONCOLOGY | 2019 | |
| 2019-08-16 | ABBVIE INC. | $193 | Research payment | Cash or cash equivalent | Lupron Depot Drug, Endocrinology | M16-904 | 2019 |
| 2019-08-15 | QOL Medical, LLC | $4,805 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUCRAID Drug, CSID | 2019 | |
| 2019-08-15 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-08-14 | Abbott Laboratories | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | 2019 | |
| 2019-08-12 | Intuitive Surgical, Inc. | $2,760 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-12 | Intuitive Surgical, Inc. | $2,760 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-12 | Intuitive Surgical, Inc. | $2,400 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-12 | Intuitive Surgical, Inc. | $2,400 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-12 | Intuitive Surgical, Inc. | $2,400 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-12 | Intuitive Surgical, Inc. | $2,400 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-08-09 | AngioDynamics, Inc. | $5,000 | Research payment | Cash or cash equivalent | Device, NanoKnife | Examining patterns of use for the NanoKnife Irreversible Electroporation Device in the real world : the NanoKnife Produc | 2019 |
| 2019-08-09 | Novocure Inc. | $2,310 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-24 Pivotal, randomized, open -label study of Tumor Treating Fields (TTFields) concurrent with standard of care thera | 2019 |
| 2019-08-08 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Fractional Flow Reserve (FFR) Device, Cardiac Arrhythmias and Heart Failure | Practical Evaluation of Fractional Flow Reserve (FFR) and its Associated Alternate Indices During Routine Clinical Proce | 2019 |
| 2019-08-07 | QOL Medical, LLC | $4,572 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUCRAID Drug, CSID | 2019 | |
| 2019-08-07 | Abbott Laboratories | $550 | Research payment | Cash or cash equivalent | AMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study | 2019 |
| 2019-08-06 | Novocure Inc. | $3,552 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-24 Pivotal, randomized, open -label study of Tumor Treating Fields (TTFields) concurrent with standard of care thera | 2019 |
| 2019-08-06 | BIOTRONIK INC. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-06 | BIOTRONIK INC. | $900 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-08-01 | Shire North American Group Inc | $750 | Research payment | Cash or cash equivalent | ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE | 2019 | |
| 2019-07-31 | LivaNova USA, Inc. | $650 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-07-30 | CSL Behring | $26,624 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-07-29 | EKOS Corporation | $2,500 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2019 |
| 2019-07-23 | Clovis Oncology, Inc. | $4,671 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-07-22 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | Lupron Depot Drug, Endocrinology | M16-904 | 2019 |
| 2019-07-18 | Novartis Pharmaceuticals Corporation | $9,972 | Research payment | Cash or cash equivalent | TAFINLAR Drug, ONCOLOGY | GSK2118436 A PHASE III RANDOMIZED OPEN LABEL STUDY COMPARING GSK2118436 TO DTIC IN PREVIOUSLY UNTREATED SUBJECTS WITH BR | 2019 |
| 2019-07-18 | Shire North American Group Inc | $2,891 | Research payment | Cash or cash equivalent | LIALDA Drug, INTERNAL MEDICINE | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY AND EFFICACY OF MMX MESALAMINE-MESALAZIN | 2019 |
| 2019-07-17 | Abbott Laboratories | $2,358 | Research payment | Cash or cash equivalent | AMPLATZER Duct Occluder II Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) Clinical Study | 2019 |
| 2019-07-11 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | HeartMate PHP Device, Cardiac Arrhythmias and Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $401 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $401 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $336 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $300 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $287 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $287 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $287 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $287 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $267 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $251 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $251 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $251 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $251 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $251 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $186 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $186 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $186 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $186 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $186 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $142 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $142 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $101 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $65 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $65 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $65 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $48 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $48 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $48 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
| 2019-07-09 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2019 |
The latest 200 records of 418.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Orlando, FL, county Orange County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Orlando, FL | County Orange County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 319,758 | 1,471,937 | 22,416,077 |
| Population, 2020 census P1 | 307,573 | 1,429,908 | 21,538,187 |
| Median age B01002 | 35.1 | 36.6 | 42.6 |
| Under 18 B01001 | 21.4% | 21.4% | 19.5% |
| 65 and over B01001 | 11.3% | 13.0% | 21.3% |
| Households B11001 | 131,179 | 527,776 | 8,752,810 |
| Foreign born B05002 | 25.4% | 24.3% | 21.9% |
| Median household income B19013 | $72,336 | $79,719 | $74,568 |
| Median family income B19113 | $81,945 | $92,968 | $89,891 |
| Per capita income B19301 | $43,312 | $41,160 | $42,609 |
| Poverty rate B17001 | 14.7% | 13.0% | 12.6% |
| Unemployment rate B23025 | 5.2% | 5.5% | 4.8% |
| Civilian labor force B23025 | 186,466 | 803,825 | 11,016,578 |
| Mean commute (minutes) B08013 | 26.2 | 28.0 | 28.0 |
| Bachelor's degree or higher B15003 | 42.5% | 39.3% | 34.1% |
| Housing units B25001 | 148,754 | 586,805 | 10,256,470 |
| Owner-occupied B25003 | 39.5% | 56.8% | 67.6% |
| Renters B25003 | 60.5% | 43.2% | 32.4% |
| Median home value B25077 | $394,100 | $390,100 | $359,000 |
| Median gross rent B25064 | $1,747 | $1,775 | $1,669 |
| White, not Hispanic B03002 | 31.2% | 35.9% | 50.4% |
| Black B03002 | 22.2% | 19.1% | 14.6% |
| Hispanic or Latino B03002 | 35.4% | 33.8% | 27.4% |
| Asian B03002 | 4.8% | 5.3% | 2.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Orlando, FL.
Comments